Long-term controlled clinical trial of a new anti-inflammatory drug, diftalone, in rheumatoid arthritis.
A long-term (two years) double-blind, comparative trial of diftalone (Aladione) 500 mg versus indomethacin 75 mg per day, in rheumatoid arthritis (thirty-two patients), has shown a similar effectiveness for both anti-inflammatory agents on various clinical parameters of disease activity, some better results being obtained for diftalone as regards the capacity of reducing erythrocyte sedimentation rate. The tolerability of diftalone proved to be somewhat superior, as is shown by the lower number of patients complaining of side-effects or being dropped out for intolerance, and by the lower frequency of central nervous system disturbances.